04.30.21

Oxurion NV Presenting Scientific Data at ARVO 2021 Annual Meeting

Source: Oxurion NV

09.01.20

Oxurion NV Reports First Patient Dosed in Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME)

Source: Oxurion NV

10.09.19

Oxurion NV to Provide Business and Clinical Update at AAO and OIS Meetings in San Francisco

Source: Oxurion NV

09.04.19

Oxurion Completes Enrollment of Phase 1 Clinical Trial Evaluating THR-687 for the Treatment of DME

Source: Oxurion NV

07.01.19

Oxurion NV Reports Topline Phase 1 Results with THR-149 for the treatment of DME

Source: Oxurion NV

05.08.19

Oxurion Issues Financial and Business Update

Source: Oxurion NV

04.24.19

Oxurion Announces Full Enrollment in its Phase 1 Trial Evaluating the Safety of its Plasma Kallikrein Inhibitor THR-149 for Treatment of DME

Source: Oxurion NV

04.04.19

Oxurion NV Announces Full Enrollment of Its Phase 2 Trial Evaluating Combination of Anti-PlGF (THR-317) and Anti-VEGF (Ranibizumab) for the Treatment of DME

Source: Oxurion NV

09.10.18

Oxurion NV Announces New NYSE Euronext Brussels Stock Ticker “OXUR” and Launch of New Website

Source: Oxurion NV

View more stories